112 related articles for article (PubMed ID: 12038797)
1. Tirofiban blocks platelet adhesion to fibrin with minimal perturbation of GpIIb/IIIa structure.
Hantgan RR; Stahle MC; Jerome WG; Nagaswami C; Weisel JW
Thromb Haemost; 2002 May; 87(5):910-7. PubMed ID: 12038797
[TBL] [Abstract][Full Text] [Related]
2. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
3. MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.
Barlage S; Wimmer A; Pfeiffer A; Rothe G; Schmitz G
Platelets; 2002 May; 13(3):133-40. PubMed ID: 12180495
[TBL] [Abstract][Full Text] [Related]
4. AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists.
Hantgan RR; Stahle MC; Connor JH; Connor RF; Mousa SA
J Thromb Haemost; 2007 Mar; 5(3):542-50. PubMed ID: 17166246
[TBL] [Abstract][Full Text] [Related]
5. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
6. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ; Jordan RE; Mascelli MA
Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
[TBL] [Abstract][Full Text] [Related]
7. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis.
Schmitt-Sody M; Metz P; Gottschalk O; Zysk S; Birkenmaier C; Goebl M; von Schulze Pellengahr C; Veihelmann A; Jansson V
Inflamm Res; 2007 Oct; 56(10):414-20. PubMed ID: 18026698
[TBL] [Abstract][Full Text] [Related]
10. Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.
Talreja D; Lubbe D; Orford JL; Lennon R; DiBattiste PM; Berger PB
J Thromb Thrombolysis; 2004 Aug; 18(1):25-30. PubMed ID: 15744550
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G
Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
[TBL] [Abstract][Full Text] [Related]
12. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.
Derhaschnig U; Pachinger C; Jilma B
Am Heart J; 2004 Apr; 147(4):E17. PubMed ID: 15077100
[TBL] [Abstract][Full Text] [Related]
13. Delineating the roles of the GPIIb/IIIa and GP-Ib-IX-V platelet receptors in mediating platelet adhesion to adsorbed fibrinogen and albumin.
Sivaraman B; Latour RA
Biomaterials; 2011 Aug; 32(23):5365-70. PubMed ID: 21529934
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of PEG-tirofiban conjugates.
Désaubry L; Riché S; Laeuffer P; Cazenave JP
Bioorg Med Chem Lett; 2008 Mar; 18(6):2028-31. PubMed ID: 18304813
[TBL] [Abstract][Full Text] [Related]
15. The disintegrin echistatin stabilizes integrin alphaIIbbeta3's open conformation and promotes its oligomerization.
Hantgan RR; Stahle MC; Connor JH; Lyles DS; Horita DA; Rocco M; Nagaswami C; Weisel JW; McLane MA
J Mol Biol; 2004 Oct; 342(5):1625-36. PubMed ID: 15364586
[TBL] [Abstract][Full Text] [Related]
16. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events.
Dunkley S; Evans S; Gaudry L; Jepson N
Platelets; 2005 Dec; 16(8):462-8. PubMed ID: 16287613
[TBL] [Abstract][Full Text] [Related]
17. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
Schwarz M; Meade G; Stoll P; Ylanne J; Bassler N; Chen YC; Hagemeyer CE; Ahrens I; Moran N; Kenny D; Fitzgerald D; Bode C; Peter K
Circ Res; 2006 Jul; 99(1):25-33. PubMed ID: 16778135
[TBL] [Abstract][Full Text] [Related]
18. Current strategies with high-dose tirofiban.
Mukherjee D; Roffi M
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):275-80. PubMed ID: 17428156
[TBL] [Abstract][Full Text] [Related]
19. [Different inhibiting effects of abciximab and tirofiban on platelet thrombus formation on a collagen surface under flow conditions].
Shimazaki T; Goto S; Sakakibara M; Eto K; Kim JY; Ichikawa N; Yoshida M; Nagaoka Y; Isshiki T; Handa S
J Cardiol; 2000 Aug; 36(2):113-21. PubMed ID: 10955255
[TBL] [Abstract][Full Text] [Related]
20. Tirofiban and emergency coronary surgery.
Shanmugam G
Eur J Cardiothorac Surg; 2005 Oct; 28(4):546-50. PubMed ID: 16126403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
